Evidence map›Paper›PMID 40289186›Full record

ArticleArchives of public health = Archives belges de sante publique2025

Hydroxychloroquine use during the first COVID-19 wave: a case study highlighting the urgent need to enhance research practices within the publication ecosystem.

Charlotte Beaudart, Flora Musuamba, Médéa Locquet, Jean-Michel Dogné, Jonathan Douxfils

Abstract read
In one paragraph

Article in Archives of public health = Archives belges de sante publique, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charlotte BeaudartUnité de recherche en pharmacologie clinique (URPC), Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, Université de Namur, Namur, Belgium.
Flora MusuambaUnité de recherche en pharmacologie clinique (URPC), Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, Université de Namur, Namur, Belgium.
Médéa LocquetUnité de recherche en pharmacologie clinique (URPC), Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, Université de Namur, Namur, Belgium.
Jean-Michel DognéUnité de recherche en pharmacologie clinique (URPC), Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, Université de Namur, Namur, Belgium.
Jonathan DouxfilsUnité de recherche en pharmacologie clinique (URPC), Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, Université de Namur, Namur, Belgium. Jonathan.douxfils@unamur.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid dissemination of scientific findings through media and social networks can profoundly impact public health policies and behaviors. However, the reliability of such data is crucial, as evidenced by significant cases like the retracted study on hydroxychloroquine (HCQ) during the COVID-19 pandemic. This paper examines the retraction of a widely publicized study by Pradelle et al., which concluded that HCQ was associated with an excess of 16,990 deaths during the pandemic's first wave. This finding was heavily influenced by a meta-analysis that did not robustly support its conclusions, particularly regarding the dose-response relationship of HCQ. Our analysis identified significant methodological flaws, including the misapplication of effect sizes and a lack of sensitivity analyses, rendering the study results unreliable. The retraction process, however, lacked transparency, failing to adequately describe in details the reasons for the study flaws to the public. This case underscores the broader challenges in scientific publishing, including the robustness of the peer-review process, the rise of fraudulent practices, and the erosion of trust in scientific institutions. We advocate for reforms to enhance transparency, improve data verification, and incentivize thorough peer review to maintain public trust and ensure the accuracy of scientific literature.

Identifiers

PMID40289186
PMCPMC12034167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.